News
Relief Therapeutics secures up to $11 Million
Relief Therapeutics, a biopharmaceutical company committed to delivering innovative treatment options for select specialities, unmet and rare diseases, announced the signing and closing of a definitive agreement with SWK Funding LLC (SWK). The transaction provides the Campus Biotech-based company with non-dilutive funding to advance its pipeline, including the clinical development of its patent-protected…
Read MoreNew X-ray world record: looking inside a microchip with 4 nanometre precision
In a collaboration with EPFL Lausanne, ETH Zurich and the University of Southern California researchers at the Paul Scherrer Institute PSI have used X-rays to look inside a microchip with higher precision than ever before. The image resolution of 4 nanometres marks a new world record. The high-resolution three-dimensional images of the type…
Read MoreAC Immune unveils novel therapeutic antibody drug conjugate (ADC)
AC Immune, unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer® Antibody Drug Conjugate) in a presentation at the annual Alzheimer’s Association International Conference, in Philadelphia, PA. Dr. Madiha Derouazi, Chief Scientific Officer of AC Immune, presented the characterization and in vitro efficacy of morADC for the first time. The talk,…
Read MoreNOA by biped marks successful market entry in Europe and the US
Navigation, Obstacle, Artificial intelligence (NOA) is the new brand name for biped’s AI mobility vest that can guide blind and visually impaired people. Following a successful market entry in ten countries, the company has signed three distribution partnerships to fie its US launch. Biped.ai specialises in innovative AI-powered navigation devices designed to enhance…
Read MoreOryl Photonics is awarded the EIC Transition grant with a European consortium
Oryl Photonics achieved a significant milestone: together with its partners of the FASS – Fast and Accurate Solubility for Sustainability project, they were awarded the prestigious EIC Transition grant amounting € 2.5 Million. The consortium is led by EU-OPENSCREEN ERIC, the European research infrastructure for early drug discovery and chemical biology with its…
Read MoreUNIGE and HUG are fighting leukaemia by targeting its stem cells
By identifying mechanisms unique to leukaemia-causing cells, a French-Swiss team has discovered a new way to fight the disease. Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva (UNIGE), University Hospital of Geneva (HUG),…
Read MoreCSEM develops a pioneering implant to support reproductive medicine
Swiss-based start-ups Impli and Yalosys, along with the technology innovation centre CSEM, announce a significant milestone in women’s healthcare—CERES. This implantable biosensor for real-time fertility hormone monitoring is now set to undergo a transformation that will make it ready for human trials by 2025. With Impli’s expertise, the biosensor has matured from a…
Read MoreUNIGE and UNIFR collaborate in breakthrough cell membranes research
UNIGE scientists have discovered how yeast cells sense physical stresses on the membranes that protect them. Cell membranes play a crucial role in maintaining the integrity and functionality of cells. However, the mechanisms by which they perform these roles are not yet fully understood. Scientists from the University of Geneva (UNIGE), in collaboration…
Read MoreRegenosca closes CHF 1Million pre-seed round
Regenosca closes CHF 1Million pre-seed round to demonstrate endoscopic delivery of TissueSpan implants. Regenosca creates unique bio-implants, enabling the body to attract and organise its own cells for seamless healing. Providing a temporary, naturally absorbed bridge, the TissueSpan technology replaces diseased tissue and restores patients to full health. With access to markets worth…
Read MoreSwiss Venture Capital Report: CHF 1.1 Billion for Swiss startups
Swiss venture capital financing remained at the low level of the previous year in the first half of 2024, with CHF 1’082.4 Million going to 138 financing rounds. Nevertheless, there were also positive signs, such as an increase in investment in the biotech sector. This half-year update to Swiss Venture Capital Report, published…
Read More